Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy

Yucai Wang, Melissa C. Larson, Steven R. Hwang, Diego Villa, Laveniya Kugathasan, Anita Kumar, Ashlee Joseph, Taylor R. Brooks, Brian T. Hill, David A. Bond, Kami J. Maddocks, Alexey Danilov, Christine Argao, Jia Ruan, Imran A. Nizamuddin, Brad S. Kahl, Natalie S. Grover, Nazneen B. Khan, Georgios N. Pongas, Izidore S. Lossos, Evguenia Ouchveridze, Aung M. Tun, Firas Baidoun, Muhamad Alhaj Moustafa, Zoey I. Harris, Javier L. Munoz, Philip R. Young, Craig A. Portell, Patrick M. Reagan, Christine E. Ryan, Reid W. Merryman, Arash Velayati, I. Brian Greenwell, Drew G. Gerber, Preetesh Jain, Michael L. Wang, Sabarish R. Ayyappan, Eric Mou, Lauren G. Banaszak, Priyanka A. Pophali, Anthony C. Stack, Marcus R. Messmer, Mayur S. Narkhede, Amitkumar Mehta, Tamara K. Moyo, Nilanjan Ghosh, Rahul S. Bhansali, Stefan K. Barta, Manali K. Kamdar, Jacob Anna, Alexander V. Stanisic, Reem Karmali, Matthew J. Maurer, James R. Cerhan, Jonathon B. Cohen, Peter Martin

Open source

DOI: 10.1038/s41408-026-01507-w
Published: 2026-04-25
Container: Blood Cancer Journal
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41408-026-01507-w,
  title = {Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy},
  author = {Yucai Wang and Melissa C. Larson and Steven R. Hwang and Diego Villa and Laveniya Kugathasan and Anita Kumar and Ashlee Joseph and Taylor R. Brooks and Brian T. Hill and David A. Bond and Kami J. Maddocks and Alexey Danilov and Christine Argao and Jia Ruan and Imran A. Nizamuddin and Brad S. Kahl and Natalie S. Grover and Nazneen B. Khan and Georgios N. Pongas and Izidore S. Lossos and Evguenia Ouchveridze and Aung M. Tun and Firas Baidoun and Muhamad Alhaj Moustafa and Zoey I. Harris and Javier L. Munoz and Philip R. Young and Craig A. Portell and Patrick M. Reagan and Christine E. Ryan and Reid W. Merryman and Arash Velayati and I. Brian Greenwell and Drew G. Gerber and Preetesh Jain and Michael L. Wang and Sabarish R. Ayyappan and Eric Mou and Lauren G. Banaszak and Priyanka A. Pophali and Anthony C. Stack and Marcus R. Messmer and Mayur S. Narkhede and Amitkumar Mehta and Tamara K. Moyo and Nilanjan Ghosh and Rahul S. Bhansali and Stefan K. Barta and Manali K. Kamdar and Jacob Anna and Alexander V. Stanisic and Reem Karmali and Matthew J. Maurer and James R. Cerhan and Jonathon B. Cohen and Peter Martin},
  year = {2026},
  journal = {Blood Cancer Journal},
  doi = {10.1038/s41408-026-01507-w},
  url = {https://doi.org/10.1038/s41408-026-01507-w}
}

RIS

TY  - JOUR
TI  - Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy
AU  - Yucai Wang
AU  - Melissa C. Larson
AU  - Steven R. Hwang
AU  - Diego Villa
AU  - Laveniya Kugathasan
AU  - Anita Kumar
AU  - Ashlee Joseph
AU  - Taylor R. Brooks
AU  - Brian T. Hill
AU  - David A. Bond
AU  - Kami J. Maddocks
AU  - Alexey Danilov
AU  - Christine Argao
AU  - Jia Ruan
AU  - Imran A. Nizamuddin
AU  - Brad S. Kahl
AU  - Natalie S. Grover
AU  - Nazneen B. Khan
AU  - Georgios N. Pongas
AU  - Izidore S. Lossos
AU  - Evguenia Ouchveridze
AU  - Aung M. Tun
AU  - Firas Baidoun
AU  - Muhamad Alhaj Moustafa
AU  - Zoey I. Harris
AU  - Javier L. Munoz
AU  - Philip R. Young
AU  - Craig A. Portell
AU  - Patrick M. Reagan
AU  - Christine E. Ryan
AU  - Reid W. Merryman
AU  - Arash Velayati
AU  - I. Brian Greenwell
AU  - Drew G. Gerber
AU  - Preetesh Jain
AU  - Michael L. Wang
AU  - Sabarish R. Ayyappan
AU  - Eric Mou
AU  - Lauren G. Banaszak
AU  - Priyanka A. Pophali
AU  - Anthony C. Stack
AU  - Marcus R. Messmer
AU  - Mayur S. Narkhede
AU  - Amitkumar Mehta
AU  - Tamara K. Moyo
AU  - Nilanjan Ghosh
AU  - Rahul S. Bhansali
AU  - Stefan K. Barta
AU  - Manali K. Kamdar
AU  - Jacob Anna
AU  - Alexander V. Stanisic
AU  - Reem Karmali
AU  - Matthew J. Maurer
AU  - James R. Cerhan
AU  - Jonathon B. Cohen
AU  - Peter Martin
PY  - 2026
JO  - Blood Cancer Journal
DO  - 10.1038/s41408-026-01507-w
UR  - https://doi.org/10.1038/s41408-026-01507-w
ER  -

APA

Wang, Y., Larson, M. C., Hwang, S. R., Villa, D., Kugathasan, L., Kumar, A., Joseph, A., Brooks, T. R., Hill, B. T., Bond, D. A., Maddocks, K. J., Danilov, A., Argao, C., Ruan, J., Nizamuddin, I. A., Kahl, B. S., Grover, N. S., Khan, N. B., Pongas, G. N., Lossos, I. S., Ouchveridze, E., Tun, A. M., Baidoun, F., Moustafa, M. A., Harris, Z. I., Munoz, J. L., Young, P. R., Portell, C. A., Reagan, P. M., Ryan, C. E., Merryman, R. W., Velayati, A., Greenwell, I. B., Gerber, D. G., Jain, P., Wang, M. L., Ayyappan, S. R., Mou, E., Banaszak, L. G., Pophali, P. A., Stack, A. C., Messmer, M. R., Narkhede, M. S., Mehta, A., Moyo, T. K., Ghosh, N., Bhansali, R. S., Barta, S. K., Kamdar, M. K., Anna, J., Stanisic, A. V., Karmali, R., Maurer, M. J., Cerhan, J. R., Cohen, J. B., & Martin, P. (2026). Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton’s tyrosine kinase inhibitor therapy. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01507-w

Source records

crossref · retrieved 2026-09-27T08:52:59.503Z